clivatuzumab tetraxetan
mAbexperimentalADC
Yttrium (90Y) clivatuzumab tetraxetan is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2004 (NCT00597129)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaYttrium (90Y) clivatuzumab tetraxetan ↗
- ChEMBLCHEMBL3301586 ↗
- ChEMBLCHEMBL2109365 ↗
- ChEMBLCHEMBL2108708 ↗
Also known as
- 90hy-pam4
- 90y-hpam4
- clivatuzumab
- clivatuzumab tetraxetan
- clivatuzumab tetraxetan
- hpam4
- hpam4 antibody
- hpam4-cide
- hpam4-dota
- hpam-dota hy-pam4
- humanized pam4 igg
- hupam4
- igg-dota
- immu-107
- immu-107
- pam4 antibody
- yttrium (90y) clivatuzumab tetraxetan
- yttrium y 90 clivatuzumab tetraxetan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01956812 | Phase 3 | Jan 1, 2014 | Immunomedics |
| NCT01510561 | Phase 1 | Mar 1, 2012 | Immunomedics |
| NCT00603863 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | Immunomedics |
| NCT00364364 | Phase 1 | May 1, 2007 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00597129 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2004 | Immunomedics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunomedics | For profit | 4 | 4 | 3 | 2004 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1